<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang K</submitter><funding>National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund)</funding><funding>National Natural Science Foundation of China (National Science Foundation of China)</funding><pagination>1011</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9950448</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Serine synthesis is crucial for tumor growth and survival, but its regulatory mechanism in cancer remains elusive. Here, using integrative metabolomics and transcriptomics analyses, we show a heterogeneity between metabolite and transcript profiles. Specifically, the level of serine in hepatocellular carcinoma (HCC) tissues is increased, whereas the expression of phosphoglycerate dehydrogenase (PHGDH), the first rate-limiting enzyme in serine biosynthesis pathway, is markedly downregulated. Interestingly, the increased serine level is obtained by enhanced PHGDH catalytic activity due to protein arginine methyltransferase 1 (PRMT1)-mediated methylation of PHGDH at arginine 236. PRMT1-mediated PHGDH methylation and activation potentiates serine synthesis, ameliorates oxidative stress, and pr</pubmed_abstract><journal>Nature communications</journal><pubmed_title>PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma.</pubmed_title><pmcid>PMC9950448</pmcid><funding_grant_id>82002963</funding_grant_id><funding_grant_id>82273122</funding_grant_id><funding_grant_id>82073081</funding_grant_id><funding_grant_id>81872277</funding_grant_id><funding_grant_id>82130082</funding_grant_id><funding_grant_id>81790251</funding_grant_id><funding_grant_id>81821002</funding_grant_id><pubmed_authors>Peng Y</pubmed_authors><pubmed_authors>Huang C</pubmed_authors><pubmed_authors>Fu S</pubmed_authors><pubmed_authors>Chen HN</pubmed_authors><pubmed_authors>Dong L</pubmed_authors><pubmed_authors>Wei X</pubmed_authors><pubmed_authors>Wang K</pubmed_authors><pubmed_authors>Shen G</pubmed_authors><pubmed_authors>Wang M</pubmed_authors><pubmed_authors>Dai L</pubmed_authors><pubmed_authors>Nice EC</pubmed_authors><pubmed_authors>Luo L</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Wu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma.</name><description>Serine synthesis is crucial for tumor growth and survival, but its regulatory mechanism in cancer remains elusive. Here, using integrative metabolomics and transcriptomics analyses, we show a heterogeneity between metabolite and transcript profiles. Specifically, the level of serine in hepatocellular carcinoma (HCC) tissues is increased, whereas the expression of phosphoglycerate dehydrogenase (PHGDH), the first rate-limiting enzyme in serine biosynthesis pathway, is markedly downregulated. Interestingly, the increased serine level is obtained by enhanced PHGDH catalytic activity due to protein arginine methyltransferase 1 (PRMT1)-mediated methylation of PHGDH at arginine 236. PRMT1-mediated PHGDH methylation and activation potentiates serine synthesis, ameliorates oxidative stress, and pr</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-05-29T19:42:53.08Z</modification><creation>2025-05-29T19:42:53.08Z</creation></dates><accession>S-EPMC9950448</accession><cross_references><pubmed>36823188</pubmed><doi>10.1038/s41467-023-36708-5</doi></cross_references></HashMap>